Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Bisphosphonates in colorectal cancer.

Limburg PJ, Singh S.

Clin Adv Hematol Oncol. 2013 Jun;11(6):372-4. No abstract available.

PMID:
24472806
2.

Use of bisphosphonates and reduced risk of colorectal cancer.

Rennert G, Pinchev M, Rennert HS, Gruber SB.

J Clin Oncol. 2011 Mar 20;29(9):1146-50. doi: 10.1200/JCO.2010.33.7485. Epub 2011 Feb 14.

3.

Individualizing therapy for metastatic colorectal cancer.

Turja J, Grothey A.

Oncology (Williston Park). 2008 Nov 30;22(13):1479-81. No abstract available.

PMID:
19227569
4.

Adjuvant chemotherapy for stage II and III colorectal cancer.

Benson AB 3rd.

Clin Adv Hematol Oncol. 2011 Aug;9(8):616-8. No abstract available.

PMID:
22236990
5.

[Bisphosphonates: less colon carcinomas].

[No authors listed]

Orthopade. 2013 Jun;42(6):454. German. No abstract available.

PMID:
23862188
6.

The use of bisphosphonates in prostate cancer.

Khan MA.

BJU Int. 2003 Jul;92(1):152. No abstract available.

7.

Recent developments in bisphosphonates for patients with metastatic breast cancer.

Gainford MC, Dranitsaris G, Clemons M.

BMJ. 2005 Apr 2;330(7494):769-73. Review. No abstract available.

8.

The crossover of bisphosphonates to cancer therapy.

Sun M, Iqbal J, Singh S, Sun L, Zaidi M.

Ann N Y Acad Sci. 2010 Nov;1211:107-12. doi: 10.1111/j.1749-6632.2010.05812.x. Review.

PMID:
21062299
9.

[Reception and adjuvant chemotherapy for metastatic site of colorectal cancer].

Nakamura M.

Gan To Kagaku Ryoho. 2014 Nov;41(11):1381-6. Japanese. No abstract available.

PMID:
25577807
10.

Recent advances in colorectal cancer therapy.

d'Entremont TS, Sun W.

Cancer Biol Ther. 2003 Jan-Feb;2(1):6-13. Review.

PMID:
12673111
11.

To resect or not the primary tumor in metastatic colorectal cancer.

Katsios CG, Baltogiannis G.

World J Surg. 2010 Oct;34(10):2492-3; author reply 2494-5. doi: 10.1007/s00268-010-0614-1. No abstract available.

PMID:
20440614
12.

Adjuvant bisphosphonates for early-stage breast cancer.

Brufsky A.

Lancet Oncol. 2011 Jul;12(7):610-1. doi: 10.1016/S1470-2045(11)70151-6. No abstract available.

PMID:
21708345
13.

Emerging role for bisphosphonates in cancer management.

Chlebowski RT.

Breast Dis. 2011;33(2):55-7. doi: 10.3233/BD-2010-0328. No abstract available.

PMID:
22142659
14.

Picking the right road for metastatic colorectal cancer patients.

Overman M, Kopetz S.

Oncology (Williston Park). 2008 Nov 30;22(13):1482-3. No abstract available.

15.

Use of bisphosphonates in the treatment of prostate cancer.

Olson KB, Pienta KJ.

Oncology (Williston Park). 2000 Sep;14(9):1361-4; discussion 1364-7. No abstract available. Erratum in: Oncology (Huntingt) 2001 Jan;15(1):13.

16.

Therapy for colorectal cancer.

Etzioni S, Rosenfeld K.

N Engl J Med. 2005 Apr 28;352(17):1820-2; author reply 1820-2. No abstract available.

PMID:
15864824
17.

[Antitumour effects of bisphosphonates in breast cancer].

van de Ven S, Kroep JR, Hamdy NA, Sleeboom HP, Nortier HW.

Ned Tijdschr Geneeskd. 2010;154:A1951. Review. Dutch.

PMID:
21083955
18.

Advanced colorectal cancer: impact of chemotherapy on survival.

Cortesi E, Padovani A, Aloe A, Picece V, Pellegrini P, Pellegrini A.

J Surg Oncol Suppl. 1991;2:112-5. Review. No abstract available.

PMID:
1892519
19.

Ziv-aflibercept (Zaltrap) for metastatic colorectal cancer.

[No authors listed]

Med Lett Drugs Ther. 2013 Apr 29;55(1415):e36. Review. No abstract available.

PMID:
23836346
20.

Bisphosphonates in the adjuvant treatment of early breast cancer: conclusion.

Eiermann W.

Crit Rev Oncol Hematol. 2010 Apr;74 Suppl 1:S16-7. doi: 10.1016/S1040-8428(10)70006-8. Review. No abstract available.

PMID:
20427028

Supplemental Content

Support Center